Evolution of the Average Target: Lineage, Inc.

Evolution of the Target Price: Lineage, Inc.

Changes in Analyst Recommendations: Lineage, Inc.

eb87458da60d.iyRA0XVgS6yHRsleloQPpGWWDI8XTvBeNSEUohyap5M._F4SnSMjAvvIIp9zwuB4_C74OPsiBb9vZFR94XutnuTlcSuwRDB-4MYykA~3146e450a7674628bf9bac8098e4b0d9
08-17 Lineage Seen Benefiting From Improving Industry Conditions, RBC Capital Markets Says MT
08-17 RBC Raises Price Target on Lineage to $48 From $44, Keeps Outperform Rating MT
07-29 Mizuho Securities Upgrades Lineage to Outperform From Neutral, Raises Price Target to $47 From $40 MT
07-21 Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike… Zonebourse
07-17 UBS Raises Price Target on Lineage to $45 From $35, Maintains Neutral Rating MT
06-17 Truist Adjusts Price Target on Lineage to $46 From $44, Maintains Buy Rating MT
06-02 Lineage Shows Early Recovery Signs as Demand Stabilizes, Morgan Stanley Says MT
06-02 Morgan Stanley Raises Price Target on Lineage to $47 From $39, Keeps Equalweight Rating MT
06-02 Analyst recommendations: Caesars Entertainment, Intuit, Caterpillar, Dell… Zonebourse
03-04 Truist Raises Price Target on Lineage to $44 From $41, Keeps Buy Rating MT
03-02 RBC Raises Price Target on Lineage to $44 From $42, Keeps Outperform Rating MT
01-20 Truist Raises Price Target on Lineage to $41 From $40, Keeps Buy Rating MT
01-14 Lineage Shares Fall After Barclays Downgrade MT
01-13 Barclays Downgrades Lineage to Equalweight From Overweight, Lowers Price Target to $38 From $47 MT
01-08 UBS Adjusts Lineage Price Target to $35 From $41, Maintains Neutral Rating MT
12-23 Truist Cuts Price Target on Lineage to $40 From $53, Keeps Buy Rating MT
12-18 Baird Downgrades Lineage to Neutral From Outperform, Adjusts PT to $39 From $45 MT
12-18 Analyst recommendations: American Express, Merck, Rivian, Albemarle, Micron… Zonebourse
11-12 RBC Lowers Price Target on Lineage to $45 From $51, Keeps Outperform Rating MT
11-11 Lineage Insider Bought Shares Worth $345,630, According to a Recent SEC Filing MT
11-06 Piper Sandler Downgrades Lineage to Neutral From Overweight, Adjusts Price Target to $41 From $55 MT
14/10/25 UBS Adjusts Price Target on Lineage to $41 From $45, Maintains Neutral Rating MT
22/08/25 Truist Cuts Price Target on Lineage to $53 From $60, Keeps Buy Rating MT
18/08/25 RBC Cuts Price Target on Lineage to $51 From $64, Keeps Outperform Rating MT
11/08/25 BofA Securities Downgrades Lineage to Underperform From Neutral MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+14.71%
+7.74%
+11.05%
+10.26%
+27.34%
+20.12%
+12.19%
+31.42%
+21.57%
- +8.96%
Average +16.54%
Weighted average by Cap. +10.57%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
39.32USD
Average target price
45.11USD
Spread / Average Target
+14.71%
High Price Target
63.00USD
Spread / Highest target
+60.22%
Low Price Target
35.00USD
Spread / Lowest Target
-10.99%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. LINE Stock
  4. Consensus Lineage, Inc.